Verrica Pharmaceuticals Inc. (VRCA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Verrica Pharmaceuticals Inc. (VRCA) Healthcare & Pipeline Overview

Verrica Pharmaceuticals Inc. is a dermatology-focused biotechnology company developing and commercializing treatments for skin diseases, primarily targeting molluscum contagiosum with its lead product candidate VP-102. The company also has ongoing trials for external genital warts and common warts, positioning it within the competitive dermatology therapeutics market.

What Is the Investment Thesis for VRCA?

Verrica Pharmaceuticals Inc. presents a focused investment opportunity within the dermatology therapeutics market. The company's lead product candidate, VP-102, targeting molluscum contagiosum, addresses a significant unmet need. Positive clinical trial results and potential FDA approval for VP-102 could drive substantial revenue growth. The company's gross margin of 90.8% indicates strong pricing power and profitability potential upon commercialization. Key growth catalysts include the successful completion of ongoing clinical trials for external genital warts and common warts, as well as expansion into new geographic markets through strategic collaborations. However, the company's negative profit margin of -50.3% and reliance on successful clinical trials and regulatory approvals pose significant risks. Investors should closely monitor clinical trial outcomes, regulatory decisions, and market adoption rates to assess the investment viability of Verrica Pharmaceuticals Inc.

Based on FMP financials and quantitative analysis

VRCA Key Highlights

Market capitalization of $82.6M reflects the company's current valuation in the biotechnology sector.

• Gross margin of 90.8% indicates strong potential profitability upon successful commercialization of its products.
• Negative profit margin of -50.3% highlights the company's current reliance on R&D and clinical trial expenses.
• Beta of 1.43 suggests higher volatility compared to the overall market, typical for biotechnology companies.
• No dividend yield reflects the company's focus on reinvesting earnings into research and development.

Who Are VRCA's Competitors?

VRCA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are VRCA's Key Strengths?

Proprietary cantharidin-based technology.

• Lead product candidate targeting a significant unmet need.
• Positive clinical trial results.
• Strategic partnerships for geographic expansion.

What Are VRCA's Weaknesses?

Negative profit margin.

• Reliance on successful clinical trials and regulatory approvals.
• Limited commercialization experience.
• Small company size and limited resources.

What Could Drive VRCA Stock Higher?

FDA decision on VP-102 approval for molluscum contagiosum.

• Completion of Phase II clinical trial for VP-102 in common warts.
• Enrollment and progress in clinical trials for VP-103 in plantar warts.
• Expansion of strategic partnerships for new markets.

What Are the Key Risks for VRCA?

Financial-distress signal — its Altman Z-Score of -13.21 sits in the distress zone (elevated bankruptcy risk).

• Failure to obtain FDA approval for VP-102.
• Unfavorable clinical trial results for VP-102 or VP-103.
• Competition from existing and emerging dermatology therapeutics.
• Dependence on strategic partners for commercialization.
• Product liability claims.

What Are the Growth Opportunities for VRCA?

• Expansion into New Therapeutic Areas: Verrica has the opportunity to expand its pipeline by developing treatments for other dermatological conditions beyond molluscum contagiosum, plantar warts, external genital warts and common warts. This could involve exploring new therapeutic targets or leveraging its existing cantharidin-based technology. The dermatology market is vast, with numerous unmet needs in areas such as acne, psoriasis, and eczema, offering significant growth potential. Timeline: Ongoing, with potential new product candidates entering clinical development within the next 2-3 years.
• Geographic Expansion: Verrica's collaboration with Torii Pharmaceutical Co., Ltd. for the Japanese market provides a template for expanding into other international markets. Europe and other regions with high healthcare spending and unmet dermatological needs represent attractive growth opportunities. Establishing partnerships or subsidiaries in these regions could significantly increase Verrica's revenue and market share. Timeline: 3-5 years, contingent on regulatory approvals and market access strategies.
• Strategic Acquisitions or Licensing: Verrica could accelerate its growth by acquiring or licensing complementary technologies or product candidates. This could involve acquiring smaller biotechnology companies with promising dermatology assets or licensing innovative drug delivery systems. Such acquisitions or licensing deals could broaden Verrica's pipeline and enhance its competitive position. Timeline: Opportunistic, dependent on available assets and strategic fit.
• Direct-to-Consumer Marketing: As Verrica's products gain regulatory approval and commercial traction, the company could explore direct-to-consumer marketing strategies to increase awareness and drive sales. This could involve online advertising, social media campaigns, and partnerships with dermatology clinics. Effective direct-to-consumer marketing could significantly boost Verrica's brand recognition and market share. Timeline: 1-2 years following successful product launches.
• Development of Combination Therapies: Verrica could explore the development of combination therapies that combine its existing product candidates with other treatments to enhance efficacy and address complex dermatological conditions. This could involve combining VP-102 with other antiviral or anti-inflammatory agents to improve treatment outcomes for molluscum contagiosum or other skin infections. Combination therapies could offer a competitive advantage and address unmet needs in the dermatology market. Timeline: 3-5 years, contingent on research and development efforts.

What Threats Does VRCA Face?

• Competition from established pharmaceutical companies.
• Regulatory hurdles and delays.
• Clinical trial failures.
• Product liability risks.

What Are VRCA's Competitive Advantages?

• Proprietary cantharidin-based technology platform.
• Clinical trial data demonstrating efficacy and safety.
• Strategic partnerships for geographic expansion.
• Intellectual property protection (patents).
• First-mover advantage in specific dermatology niches.

What Does VRCA Do?

Verrica Pharmaceuticals Inc., established in 2013 and headquartered in West Chester, Pennsylvania, is a dermatology therapeutics company dedicated to developing and commercializing innovative treatments for skin diseases. The company's primary focus is on addressing unmet needs in dermatology through its proprietary product candidates. Verrica's lead product candidate, VP-102, is being developed for the treatment of molluscum contagiosum, a common viral skin infection. VP-102 has completed Phase II clinical trials for external genital warts and is in Phase II clinical trials for common warts, demonstrating its potential across multiple dermatological indications. In addition to VP-102, Verrica is also developing VP-103, a cantharidin-based product candidate for treating plantar warts. These product candidates leverage Verrica's expertise in dermatology and its commitment to providing effective solutions for patients with skin diseases. Verrica has also established strategic collaborations to expand its reach and pipeline. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates in Japan, focusing on molluscum contagiosum and common warts. Additionally, Verrica has a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications, further diversifying its therapeutic focus. With a team of 71 employees, Verrica is focused on advancing its pipeline and commercializing its products to improve the lives of individuals affected by skin diseases.

What Products and Services Does VRCA Offer?

• Develops and commercializes dermatology therapeutics.
• Focuses on treatments for skin diseases.
• Lead product candidate: VP-102 for molluscum contagiosum.
• Conducts clinical trials for external genital warts and common warts.
• Developing VP-103 for plantar warts.
• Collaborates with Torii Pharmaceutical for Japanese market.
• Partners with Lytix Biopharma for dermatological oncology.

How Does VRCA Make Money?

• Develops proprietary dermatology therapeutics.
• Conducts clinical trials to demonstrate safety and efficacy.
• Seeks regulatory approvals for commercialization.
• Commercializes products directly or through partnerships.
• Generates revenue through product sales and licensing agreements.

What Industry Does VRCA Operate In?

Verrica Pharmaceuticals Inc. operates within the dermatology therapeutics market, a segment experiencing growth driven by increasing prevalence of skin diseases and demand for innovative treatments. The market is characterized by intense competition among established pharmaceutical companies and emerging biotechnology firms. Verrica's focus on molluscum contagiosum and other common skin conditions positions it within a niche market with significant potential. The company's success depends on its ability to navigate the competitive landscape, secure regulatory approvals, and effectively commercialize its products.

Who Are VRCA's Key Customers?

• Patients with skin diseases (molluscum contagiosum, warts).
• Dermatologists and other healthcare providers.
• Pharmacies and distributors.
• Strategic partners (Torii Pharmaceutical, Lytix Biopharma).

Company Profile

Verrica Pharmaceuticals Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in West Chester, US. The company is led by CEO Jayson Rieger. VRCA has traded publicly since 2018.

Verrica Pharmaceuticals Inc. Financial Trajectory

Verrica Pharmaceuticals Inc. (VRCA) reported $5.9M in revenue for Q2 FY2026, reflecting 16.7% growth compared to the prior quarter. The company recorded a net loss of $13.2M, with diluted EPS of $-0.62. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, VRCA averaged $-0.46 in diluted EPS.

How Verrica Pharmaceuticals Inc. Is Valued

Verrica Pharmaceuticals Inc. carries a market capitalization of $82.6M, placing it in the micro-cap category. Analyst price targets span from $9.00 to $9.00, with a consensus of $9.00. At the current price of $4.81, that implies approximately 87% upside potential. Relative to its peer group, VRCA's quantitative score of 19/100 is below the peer average of 77/100.

Key Financial Metrics

Return on assets is -86.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -15.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.45 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -29.6%, the inverse of the P/E and a quick read on earnings relative to price.

Verrica Pharmaceuticals Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -13.21 places it in the distress zone, a signal of elevated financial risk.

Verrica Pharmaceuticals Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 63.9% below estimates on average.

Over the past six months, Verrica Pharmaceuticals Inc. insiders filed 13 SEC Form 4 transactions — 0 sales and 13 purchases. On net that is roughly 1.0M shares acquired (about $8.1M) — insiders putting money in tends to read as conviction.

VRCA Financials

VRCA Latest News

VRCA Analyst Consensus

VRCA MoonshotScore

Common Questions About VRCA (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources